Evidence map›Paper›PMID 29741665›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018

Evaluation of Preexposure (PrEP) Eligibility Criteria, Using Sexually Transmissible Infections as Markers of Human Immunodeficiency Virus (HIV) Risk at Enrollment in PrEPX, a Large Australian HIV PrEP Trial.

Vincent J Cornelisse, Christopher K Fairley, Mark Stoove, Jason Asselin, Eric P F Chow, Brian Price, Norman J Roth, Jeff Willcox, B K Tee, Matthew Penn and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Vincent J CornelisseCentral Clinical School, Monash University, Melbourne.
Christopher K FairleyCentral Clinical School, Monash University, Melbourne.
Mark StooveThe Burnet Institute, Prahran.
Jason AsselinThe Burnet Institute, Prahran.
Eric P F ChowCentral Clinical School, Monash University, Melbourne.
Brian PriceDepartment of Infectious Diseases, The Alfred Hospital, Alfred Health, Prahran.
Norman J RothDepartment of Infectious Diseases, The Alfred Hospital, Alfred Health, Prahran.
Jeff WillcoxNorthside Clinic, Fitzroy North.
B K TeeThe Victorian AIDS Council.
Matthew PennThe Victorian AIDS Council.
Christina C ChangCentral Clinical School, Monash University, Melbourne.
Judith ArmishawDepartment of Infectious Diseases, The Alfred Hospital, Alfred Health, Prahran.
George Forgan-SmithERA Health, Melbourne, Victoria, Australia.
Edwina J WrightCentral Clinical School, Monash University, Melbourne.
PrEPX Study Team
The Alfred Hospital · AUBurnet Institute · AUMelbourne Sexual Health Centre · AUNational AIDS Council · ZWNorthside Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To determine participants' human immunodeficiency virus (HIV) risk, the Australian preexposure prophylaxis (PreEPX) trial used 6 eligibility criteria derived from the US Centers for Disease Control and Prevention PrEP guidelines. Participants who fulfilled no eligibility criteria could be enrolled if clinically assessed to need PrEP. This study evaluated whether PREPX eligibility criteria correlated with biological HIV risk markers-namely, syphilis, anorectal chlamydia, or anorectal gonorrhea (sexually transmitted infections [STIs]). Methods: We calculated adjusted odds ratios (aORs) to assess whether eligibility criteria predicted STI diagnoses at enrollment. Results: We included 1774 participants, of whom 10.2% tested positive for STIs. Eligibility criteria predicted STI diagnoses as follows: (1) aOR 2.5 (95% confidence interval [CI], 1.4-4.4) for condomless anal intercourse (CLAI) with an HIV-positive regular sexual partner (RSP) with detectable viral load; (2) aOR 1.8 (95% CI, 1.3-2.5) for receptive CLAI with casual sexual partners; (3) aOR 1.8 (95% CI, 1.3-2.5) for previous STIs; (4) aOR 2.1 (95% CI, 1.4-3.0) for methamphetamine use; (5) aOR 0.8 (95% CI, .6-1.1) for unsuccessful condom use; and (6) aOR 1.0 (95% CI, .7-1.4) for insertive CLAI when uncircumcised. Of participants enrolled outside eligibility criteria, 7.1% had STIs. Conclusions: Eligibility criteria 1-4 predicted diagnoses of STIs, but eligibility criteria 5 and 6 did not. Our findings support the use of PrEP eligibility criteria recommended in current guidelines. Participants enrolled outside the eligibility criteria had substantial prevalence of STIs, suggesting that people who request PrEP but do not fulfill eligibility criteria may nonetheless need PrEP.

Indexed as

Patient SelectionPre-Exposure ProphylaxisChlamydia InfectionsClinical Trials as TopicGonorrheaHIV InfectionsHumansMaleOdds RatioPrevalenceRisk FactorsSexual BehaviorSexually Transmitted DiseasesSexual PartnersSyphilisUnsafe Sex

Identifiers

PMID29741665
PMCPMC6260154
OpenAlexW2801797051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.